Genetic engineering of the pseudorabies virus genome to construct live vaccines.
Pseudorabies virus (PRV) is a herpesvirus of pigs. Homologous recombination with plasmids offers a method to engineer precise changes in the PRV genome to produce advantageous live vaccines. Safety can be ensured by using a non-reverting deletion to inactivate the thymidine kinase gene. One particularly important feature of new PRV vaccines is deletion of an antigen, so that vaccinated pigs are serologically distinguishable from infected pigs. We have constructed a live vaccine strain with deletions in the thymidine kinase gene and in the gene for a glycoprotein, gX. Molecular engineering techniques made it possible to choose deletion of gX, which has no known immunological significance, over deletion of other glycoproteins that contribute to protective immunity. Extensive experiments in pigs with isogenic virus pairs show that deletion of gX does not compromise efficacy of a vaccine as gI deletions do. Deletion of gX also suggests a site for replacement with antigens from other pathogens. In addition to molecular engineering of a live vaccine strain, research on PRV glycoproteins has led to the discovery that expression of the glycoprotein gp50 makes cells resistant to PRV infection. Perhaps this observation could be extrapolated to the level of a whole animal to allow engineering of pigs to become an alternative to engineered vaccines.
Post
L E
LE
Upjohn Company, Kalamazoo, Michigan 49007.
Thomsen
D R
DR
Petrovskis
E A
EA
Meyer
A L
AL
Berlinski
P J
PJ
Wardley
R C
RC
D000818:Animals; D011558:Herpesvirus 1, Suid / Q000235:genetics* / Q000276:immunology; D011557:Pseudorabies / Q000517:prevention & control; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control; D014614:Vaccines, Synthetic / Q000627:therapeutic use*; D014759:Viral Envelope Proteins / Q000235:genetics; D014765:Viral Vaccines / Q000627:therapeutic use*
D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C042966:pseudorabies virus glycoproteins